Background: Randomized controlled trial to evaluate synergy between taxane plus platinum chemotherapy and CADI-05, a Toll like receptor-2 agonist targeting desmocollin-3 as a first-line therapy in advanced non-small-cell lung cancer (NSCLC).
Introduction
Cancer development and progression are associated with failure of immune system to mount effective antitumor immune response [1] . Antitumor immune response is a balance between immune effector function and immune suppression in tumor microenvironment and tumor infiltrating immune cells [2] . Chemotherapy like cisplatin and paclitaxel tilts the balance in favor of effector function by killing cancer cells, decreasing immunosuppressive cells like T regs and activating T cells [3] . The tilt toward effector function is seen only in responders [4] [5] [6] while increased immunosuppression is seen in nonresponders [4] [5] [6] . Cisplatin and paclitaxel also sensitize tumor cells to lymphocyte mediated killing at therapeutic and sub-therapeutic dose in sensitive and resistant cells [7, 8] .
CADI-05 is a potent Toll-like receptor-2 agonist [9] , which induces cell-mediated immune response targeting desmocollin-3 (DSC3)-expressing cancer cells, the immune response generated is pure Th1 type [10, 11] . The administration of CADI-05 to DSC3 expressing small-size tumor-bearing animals results in delayed tumor progression with improved survival but has no effect on larger tumor [10, 12] . CADI-05 is found to be synergistic with chemotherapy and monoclonal antibodies targeting immune check point [10, 12] . Response to CADI-05 is associated with increased TIL comprising of interferon-c-secreting CD4 cells, CD8 cells, NK cells, NKT cells, and macrophages. It also decreases tumor infiltrating Treg cells. There is increased intratumoral Teff/Treg ratio with change in macrophage profile from M2 to M1 [10] [11] [12] . No change in tumor infiltrating cells is seen in large tumors not responding to CADI-05 [12] .The cancer cell killing effect is mainly through CD8 þ T cells secreting IFN-c [11] .
In preliminary human clinical studies, the addition of CADI-05 to chemotherapy in non-small-cell lung cancer (NSCLC) [13] and radiotherapy in muscle invasive bladder cancer was found to improve outcome [14] . As a monotherapy, it is found useful in the management of advanced melanoma [15] . We conducted this study to confirm findings of the previous study [13] , wherein the addition of CADI-05 to chemotherapy improved objective response rate (ORR), progression-free survival PFS, and overall survival (OS) in patients with advanced NSCLC.
Patients and methods

Patients
This multicenter, open-label, controlled clinical trial enrolled participants of either sex who were >18 years of age and were willing to give informed consent with newly diagnosed advanced (stage III and/or IV) treatment naive NSCLC as confirmed by histopathology or cytology analysis. Driver gene alteration analysis was not carried out. Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and adequate hematologic, hepatic, and renal functions along with negative pregnancy test for women having child bearing potential. Patients who had received prior cytotoxic chemotherapy or radiotherapy, those with symptomatic brain metastasis and with history of allergic reactions to study drugs or any of their ingredients were excluded from the trial.
Study design and treatment
Between June 16, 2008, and July 4, 2009, 221 patients were recruited at 15 active sites in different parts of India and followed up until July 21, 2010, with a total patient participation time of 2 years and 35 days. Using block randomization, patients were assigned in a 1 : 1 ratio to receive cisplatin plus paclitaxel alone (chemotherapy group). or with CADI-05 (chemoimmunotherapy group). All the patients received a 3-hour infusion of 175 mg/m 2 of paclitaxel, immediately followed up by 1-hour infusion of 100 mg/m 2 of cisplatin on the first day of a 21-day cycle for a total of four cycles. Additionally, in the chemoimmunotherapy group, 0.2 ml of CADI-05 (0.50 Â 109 killed mycobacterium w per 0.1 ml) over each deltoid, (supplementary Table S1 , available at Annals of Oncology online) was administered intradermaly a week before initiating chemotherapy. Subsequently, 0.1 ml of CADI-05 was administered on days 8 and 15 of each cycle and then every month thereafter for a total of 12 months or until progression of disease or death, whichever was earlier.
Assessments
The primary end point OS was assessed as the time between randomization and death or last contact (censored nonevent) and PFS was assessed as the time between randomization and disease progression or death. The secondary end point, response rate, was measured by radiological assessments with computed tomography (CT) at baseline, end of two cycles and four cycles using Response Evaluation Criteria in Solid Tumors (RECIST) by an independent radiologist. Moreover, tumor evaluation was repeated every 3 months till disease progression or death for 1 year. Toxic effects were assessed according to the Common Toxicity Criteria of the National Cancer Institute (version 3.0).
Medication history, physical examination, and performance status were recorded during each scheduled visit. Complete blood count, liver function tests, renal function tests, lactate dehydrogenase, blood urea nitrogen, serum electrolytes, and bicarbonates were measured on day 1 of each chemotherapy schedule and at each subsequent scheduled visit. 
Statistical analysis
OS, which was the primary efficacy end point, was analyzed with the use of the Kaplan-Meier method and a stratified log-rank test. For the final analysis, the survival status of all patients was updated within 1 month before the data cutoff date (September 2012). Data from patients who were alive were censored for the survival analysis. A multivariate analysis of survival was carried out with the use of a Cox proportional hazards model to evaluate the treatment effect with adjustment for stratification factors. The comparison of the response rates between the treatment groups was carried out with the use of the chisquare test. All statistical analysis of survival and hazard functions were carried out by using PROC LIFETEST of SAS statistical software version 9.1.3 (SAS Institute Inc; CARY R, USA). The progression-free and OS probabilities were analyzed by Cox-Mantel chi-square (log-rank) test followed by Cox regression test.
Post hoc analysis of PFS and OS data for disease types (adenocarcinoma, squamous cell carcinoma, and other types of advanced disease), stages (IIIB and IV), and responders versus nonresponders were carried out as per the procedures described in the preceding paragraph. 
Ethical and regulatory considerations
Results
Patient characteristics
A total of 250 patients were screened, of whom 221 were randomized to either of the groups. Among them, 156 patients completed two cycles and 126 patients completed the four cycles of chemotherapy. Per-protocol analysis (PPA), represents data for protocol compliant patients who completed four chemotherapy cycles (59 and 67 patients in the chemoimmunotherapy and chemotherapy groups, respectively). Intention-to-treat (ITT) represents data analysis for all 221 patients (109 and 112 in the chemoimmunotherapy and chemotherapy groups, respectively) ( Figure 1 ). There were no significant differences between the gender, age, weight, bovine serum albumin, ECOG performance status, stage and disease type between two groups as per ITT and PPA (Table 1) . None of the participants received second-line or maintenance therapy.
Efficacy
In ITT population, median OS did not differ statistically between the two groups [208 versus 196 days; hazard ratio, 0.86; 95% confidence interval (CI) 0.63-1.19; P ¼ 0.3804] ( Figure 2B ). However, in PPA population, the chemoimmunotherapy group had improved median OS by 66 days as compared with the chemotherapy group (299 versus 233 days; hazard ratio, 0.64; 95% CI 0.41-0.98; P ¼ 0.04) (Figure 2A ). This was also associated with improved survival rate by 17.48% at the end of 1 year, i.e. 33.89% (20 of 59) versus 16.41% (11 of 67) in the chemoimmunotherapy group.
Chemoimmunotherapy improved median PFS significantly in PPA population (253 versus 157 days; hazard ratio, 0.43; 95% CI 0.25 to 0.73; P ¼ 0.0019) ( Figure 2C ) with trend toward improvement in ITT (199 versus 97 days; hazard ratio, 0.69; 95% CI 0.47-1.002; P ¼ 0.052) ( Figure 2D ).
Chemoimmunotherapy improved OS (hazard ratio, 0.67; 95% CI 0.47-0.96; P ¼ 0.03) and PFS (hazard ratio, 0.49; 95% CI 0.32-0.76; P ¼ 0.003) also in those who received at least two cycles of chemotherapy (supplementary Figure S1 , available at Annals of Oncology online).
There was an improvement in overall response rate by 10% (47% in the chemoimmunotherapy group to 37% in the chemotherapy group) at the end of four cycles of treatment in those who completed four cycles of chemotherapy (see supplementary Table S2 , available at Annals of Oncology online). The chemoimmunotherapy group with a complete response in three patients in the chemoimmunotherapy group and none in the chemotherapy group. Disease remained stable in 42% of patients in the chemoimmunotherapy group and 48% of patients in the chemotherapy group, whereas progression of disease was observed in 11% and 16% of patients in the chemoimmunotherapy and chemotherapy groups, respectively.
Subgroup analysis
The subgroup analysis revealed maximum treatment benefit of the chemoimmunotherapy in squamous NSCLC (Figure 3 2E).For adenocarcinoma and others, there was a trend toward improvement in the median survival ( Figure 3) . The trend toward the benefit of chemoimmunotherapy seemed to be better with better performance status (ECOG0 versus ECOG01), less advanced disease (stage IIIB versus stage IV), and nonsmokers versus smokers. No benefit was seen in nonresponders.
Safety
All the patients who received one dose of chemotherapy (104 in the chemotherapy group and 92 patients in the chemoimmunotherapy group) were included in the safety analysis. Treatment emergent (chemotherapy) clinical adverse events (AEs) like nausea and vomiting (P ¼ 0.6035), diarrhea (P ¼ 0.0737), pain (P ¼ 0.6282), weakness (P ¼ 0.3121), weight loss (P ¼ 0.6035), anorexia (P ¼ 0.6352), neuropathy (P ¼ 0.3383), and alopecia (P ¼ 0.6867) reported in both the groups were not significantly different. (see supplementary Table  S3 , available at Annals of Oncology online). As anticipated, the most common AEs in both the groups including hematological and nonhematological were chemotherapy associated, were grade 1 or 2 toxic effects, and were comparable. Although both the groups had fewer and comparable grade 3 and grade 4 laboratory toxicities, no grade 3 or 4 AEs related to CADI-05 was reported. Moreover, one gastrointestinal and two auditory-related Serious Adverse Events (SAEs) occurred in the chemoimmunotherapy group related to chemotherapy and were declared as expected by investigator's assessment. Chemotherapy dose modifications and dose delays were identical in both the groups (see supplementary  Tables S4 and S6 , available at Annals of Oncology online). Granulocyte colony-stimulating factor was administered in seven patients in both the groups. A total of 55 deaths were reported before the completion of treatment with 23 deaths in the chemoimmunotherapy group and 32 deaths in the chemotherapy group. Additionally, 67 and 59 patients completed four chemotherapy cycles among the chemotherapy and chemoimmunotherapy groups, respectively. None of the deaths were attributed to the study drug.
Injection site-related AEs were significantly (113 versus 3; P < 0.0001) higher in the chemoimmunotherapy group than in the chemotherapy group.
Discussion
The advantage of addition of CADI-05 to platinum containing doublet was not seen as per ITT analysis, but improvement in OS, PFS, and ORR was seen in those completing four cycles of chemotherapy. The discrepancy can be due to inability of significant number of patients to complete planned four cycles of chemotherapy as outlined in both groups (Table 1) . There was no increase in systemic serious AEs or AE attributable to addition of CADI-05. Injection site reaction was the only additional side-effect observed. Thus, the addition of CADI-05 to platinum containing doublet is safe. This is in contrast to AE seen when bevacizumab [16] or necitumumab is added to platinum containing doublet [17] .
The subgroup analysis revealed maximum treatment benefit of chemoimmunotherapy in squamous NSCLC (Figure 3 ) with improved median OS by 127 (299 versus 172 days; hazard ratio, 0.55; 95% CI 0.32-0.95; P ¼ 0.046) ( Figure 2F ) as per ITT and 110 days (364 versus 254 days; hazard ratio, 0.40; 95% CI 0.17-0.96; P ¼ 0.04) ( Figure 2E ) as per PPA. For adenocarcinoma and others, there was a trend toward improvement in the median survival ( Figure 3) . The trend toward the benefit of chemoimmunotherapy seemed to be better with better performance status (ECOG0 versus ECOG01), less advanced disease (stage IIIB versus stage IV), and nonsmokers versus smokers. No benefit was seen in nonresponders. The benefit seen in squamous NSCLC may be due to described presence of DSC3 in squamous NSCLC in literature, and its absence in nonsquamous NSCLC before the initiation of chemotherapy [18, 19] since CADI-05 induces cell-mediated immune response targeting DSC3-expressing cancer cells.
The trend toward better benefit of chemoimmunotherapy for ECOG0 versus ECOG1, stage IIIB versus stage IV may be due to relatively lower immunosuppression in these groups. The trend toward better benefit among nonsmoker seen in this study compared with smokers is in contrast to observation with anti-Programmed cell death Protein-1 (PD-1) therapy. This may be due to difference in mechanism of action of both therapies. Anti-PD-1 therapy is nonspecific passive immunotherapy and is believed to need the presence of neoantigens/mutated genes which are more frequent in smokers and within tumor for its efficacy [20] . In contrast, CADI-05 has a specific target desmocollin-3-expressing tumor cells.
Immunotherapy is associated with delayed benefit (improved survival in absence of ORR), making RECIST criteria inadequate for evaluation of response to therapy [21] . Subgroup analysis as per response to therapy did not reveal any delayed benefit in nonresponders. This is contrary to what is observed with check point inhibitors [21] [22] [23] . Check point inhibitors decreases resistance to adaptive immune response and is associated with increased infiltration of tumor with CD8 cells [23] . In large-size tumor-bearing animals, CADI-05 fails to increase infiltration of CD8 cells and needs additional therapy to reduce immunosuppression to achieve increased infiltration of CD8 cells [12] . Chemotherapy is known to reduce immunosuppression in responders only [4] [5] [6] . There is increased immunosuppression in nonresponders [4] [5] [6] . The absence of help from chemotherapy in nonresponders may explain the lack of delayed benefit in this study.
In conclusion, th benefit of addition of CADI-05 to cisplatinpaclitaxel as improved ORR, PFS, and OS was seen only in those receiving four cycles of chemotherapy for management of newly diagnosed treatment naive advanced (stage IIIB/IV) NSCLC patients . Benefit was not seen in ITT analysis. Benefit was maximum in squamous NSCLC, known to express DSC3, in ITT analysis as well as those who received four cycles of chemotherapy.
